This study critically evaluates all the previous studies on Copaxone. The conclusion is that Copaxone is indeed an effective therapy for Multiple Sclerosis-- an important deduction considering that there is always some controversy bouncing around regarding Copaxone's efficacy, given that it is very different in its approach than the other proven treatments.
"Glatiramer acetate (Copaxone®, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS)...
The efficacy of glatiramer acetate is stable or may increase over time and the drug has a favourable side effect profile. Glatiramer acetate is an appropriate first-line immunomodulatory therapy for RR MS."
Click "read more" for the full abstract...
Full Article Text
Expert Opinion on Pharmacotherapy
2004, vol. 5, no. 4, pp. 875 - 891
Glatiramer acetate for the treatment of multiple sclerosis
Jerry S Wolinsky
Abstract
Glatiramer acetate (Copaxone®, Teva Pharmaceuticals Ltd) is a collection of immunomodulatory, synthetic polypeptides indicated for the treatment of relapsing-remitting multiple sclerosis (RR MS). Preclinical and clinical studies provide an evolving understanding of the mechanisms by which glatiramer acetate exerts both immunological and potential neuroprotective effects that account for its clinical efficacy. The results of pivotal controlled clinical trials and long-term data, derived from organised extension studies, are evaluated in detail and supportive data from open-label comparison, combination treatment and therapeutic switch studies are considered in order to determine the place of glatiramer acetate among other approved therapies for RR MS. The efficacy of glatiramer acetate is stable or may increase over time and the drug has a favourable side effect profile. Glatiramer acetate is an appropriate first-line immunomodulatory therapy for RR MS.
Original article can be found here
